This review used network analysis to evaluate four drugs as second-line therapy for non-small cell lung cancer. It found erlotinib, docetaxel and gefitinib were significantly effective compared to placebo. There were no significant effect differences between docetaxel and erlotinib, gefitinib or pemetrexed. Given potential limitations in the review process and study quality, the reliability of the authors' conclusions is unclear.
To evaluate the efficacy of erlotinib, docetaxel, gefitinib and pemetrexed as second-line therapy for non-small cell lung cancer using a network analysis.
Searching
MEDLINE and EMBASE were searched from January 1997 to October 2007 for publications in English. Search terms were not reported, but were available from the authors. Presentations at recent oncology conferences were searched for unpublished studies. Bibliographies of each retrieved article were handsearched.
Study selection
Randomised controlled trials (RCTs) that evaluated erlotinib, docetaxel, gefitinib or pemetrexed as second-line therapy for stage III/IV patients with non-small cell lung cancer were eligible for inclusion. Eligible trials had to include at least some patients with stage III/IV disease who had received previous chemotherapy. The included trials had to use the drugs at their licensed doses: erlotinib 150mg/day; docetaxel 75mg/m 2 every 21 days; gefitinib 250 mg/day; and pemetrexed 500mg/m 2 every 21 days. Trials using concomitant radiotherapy were excluded. The eligible outcome was the hazard ratio for overall survival.
In included trials, treatment duration (where given) ranged from 2.7 to four months. The included trials either compared drug with placebo or compared two different drugs. Most included patients had received one previous course of chemotherapy, but a significant minority had received more. The median age range of patients was 57 to 63 years; the proportion of females ranged from 25% to 36%; their performance status was mostly Eastern Cooperative Oncology Group status 1 or 2 (details of disease stage were provided).
Two reviewers performed the selection.
Assessment of study quality
Methodological quality was assessed using the method of Jadad and Schulz. Quality scores were reported, with a maximum of 5 points for criteria including randomisation, blinding, and treatment of withdrawals and drop-outs.
The authors did not report how many reviewers performed the quality assessment.
Data extraction
The number of events for each outcome was extracted in order to calculate hazard ratios (HR) and 95% confidence intervals (CI).
The authors did not report how many reviewers performed the extraction.
Methods of synthesis
A network analysis was performed in order to compare treatments using indirect evidence; this meta-analysis used mean
